secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kairos Pharma, LTD. (KAPA)
CIK:        0001962011
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0001493152-26-008116
Event type: m_and_a
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kairos Pharma signs term sheet to acquire two lung cancer assets from Celyn Therapeutics
--------------------------------------------------------------------------------

- Worldwide rights to CL-273 (pre-IND pan-EGFR inhibitor) and CL-741 (Phase 1-ready c-MET inhibitor) for NSCLC.
- No financial terms or expected close date disclosed in press release or filing.
- CL-273 is wild-type-sparing with 4-5x wider safety margin; CL-741 targets MET-amplification resistance.
- Celyn backed by OrbiMed and Torrey Pines Investment; Kairos plans to use Cedars-Sinai clinical network.
- Acquisition aims to address EGFR-mutant and c-MET-driven lung cancer resistance mechanisms.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1962011/000149315226008116/0001493152-26-008116-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1962011/000149315226008116/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-008116

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer